Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Studied at 250-1,000 mg/day NMN for 6-12 weeks; NAD+ rises, but no cellular health outcome has been established
- Expected timeframe
- Not established
Protocol
- form
- Not applicable; regulatory status is contested, with NMN excluded from the US supplement market by FDA determination
- duration
- Not applicable
- co factor
- Evidence is insufficient, and cellular health is not a measurable endpoint. NAD+ is genuinely central to cellular function - it is the electron carrier in glycolysis and oxidative phosphorylation, the substrate for sirtuins and PARP enzymes involved in DNA repair, and its levels decline with age in multiple tissues. NMN supplementation at 250-1,000 mg/day reliably raises blood NAD+ in human trials lasting 6-12 weeks. The gap is between that biochemistry and any demonstrated cellular or clinical benefit: no human trial has shown improved mitochondrial function, reduced senescent cell burden, improved DNA repair capacity or any downstream cellular outcome. Raising a metabolite is not the same as improving cell health, and the assumption that more NAD+ is uniformly better has not been tested.
- titration
- Not applicable
- starting dose
- Not established
Evidence
What the studies say
No studies are yet linked to both NMN and Cellular Health.
Safety
Caveats
Cellular health is a marketing frame with no corresponding test, and should not be the basis for buying a supplement. NMN raises NAD+; everything beyond that is extrapolation from mouse and cell culture work. Regulatory note: the US FDA has determined NMN is excluded from the dietary supplement definition, and availability differs by country. Safety: trials up to 1,000 mg/day over 6-12 weeks report good tolerability, with occasional nausea, diarrhoea, headache and flushing. There is no established upper intake level and no long-term human safety data. A theoretical concern worth stating plainly: NAD+ supports cell proliferation and DNA repair, processes that cancer cells also use, and preclinical work raises the possibility that NAD+ precursors could support tumour growth - anyone with a current or previous cancer should discuss NMN with their oncologist before use. Interactions are poorly characterised, and NMN is often sold alongside resveratrol and other compounds with their own interaction profiles. Avoid in pregnancy and breastfeeding, where no safety data exist. Exercise remains the intervention with the best evidence for mitochondrial function.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.